Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2012-01-09836,2012,Rajasingham 2012 PLoS Med,17,Amphotericin B (1.0 mg/kg/d) for 7 days + fluconazole (1200 mg/d) for 14 days VERSUS Fluconazole (1200 mg/d) for 14 days IN HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa,23055838,HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa,Amphotericin B (1.0 mg/kg/d) for 7 days + fluconazole (1200 mg/d) for 14 days,Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis.,Fluconazole (1200 mg/d) for 14 days,NE
2012-01-09836,2012,Rajasingham 2012 PLoS Med,60,Fluconazole + flucytosine (5FC) (100 mg/kg/d) + fluconazole (1200 mg/d) for 14 days VERSUS Fluconazole (1200 mg/d) for 14 days IN HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa,23055838,HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa,Fluconazole + flucytosine (5FC) (100 mg/kg/d) + fluconazole (1200 mg/d) for 14 days,Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis.,Fluconazole (1200 mg/d) for 14 days,NE
2012-01-09836,2012,Rajasingham 2012 PLoS Med,77,Amphotericin B (0.7 mg/kg/d) for 14 days + fluconazole (800 mg/d) for 14 days VERSUS Fluconazole (1200 mg/d) for 14 days IN HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa,23055838,HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa,Amphotericin B (0.7 mg/kg/d) for 14 days + fluconazole (800 mg/d) for 14 days,Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis.,Fluconazole (1200 mg/d) for 14 days,NE
2012-01-09836,2012,Rajasingham 2012 PLoS Med,87,Amphotericin B (0.7-1.0 mg/kg/d) for 14 days + 5FC (100 mg/k/d) for 14 days VERSUS Fluconazole (1200 mg/d) for 14 days IN HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa,23055838,HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa,Amphotericin B (0.7-1.0 mg/kg/d) for 14 days + 5FC (100 mg/k/d) for 14 days,Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis.,Fluconazole (1200 mg/d) for 14 days,NE
2012-01-09836,2012,Rajasingham 2012 PLoS Med,91,Amphotericin B (0.7 mg/kg/d) for 14 days VERSUS Fluconazole (1200 mg/d) for 14 days IN HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa,23055838,HIV-infected adults with crptococcal meningitis in resource-limited settings of sub-Saharan Africa,Amphotericin B (0.7 mg/kg/d) for 14 days,Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis.,Fluconazole (1200 mg/d) for 14 days,NE
2011-01-07275,2011,Walensky 2011 J Acquir Immune Defic Syndr,1800,One time HIV screening VERSUS Current practice IN General population of South Africa,21068674,General population of South Africa,One time HIV screening,"The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa.",Current practice,NE
2011-01-07275,2011,Walensky 2011 J Acquir Immune Defic Syndr,2000,HIV screening every 5 years VERSUS Current practice IN General population of South Africa,21068674,General population of South Africa,HIV screening every 5 years,"The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa.",Current practice,NE
2011-01-07275,2011,Walensky 2011 J Acquir Immune Defic Syndr,2200,Annual HIV screening VERSUS Screening every 5 years IN General population of South Africa,21068674,General population of South Africa,Annual HIV screening,"The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa.",Screening every 5 years,NE
2011-01-07271,2011,Bendavid                         2011 AIDS,1300,Tenofovir + lamivudine + nevirapine VERSUS Zidovudine + lamivudine + nevirapine IN HIV patients in South Africa,21124202,HIV patients in South Africa,Tenofovir + lamivudine + nevirapine,Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.,Zidovudine + lamivudine + nevirapine,NE
2011-01-07271,2011,Bendavid                         2011 AIDS,7200,Tenofovir + lamivudine + efavirenz VERSUS Tenofovir + lamivudine + nevirapine IN HIV patients in South Africa,21124202,HIV patients in South Africa,Tenofovir + lamivudine + efavirenz,Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.,Tenofovir + lamivudine + nevirapine,NE
2011-01-07271,2011,Bendavid                         2011 AIDS,Dominated,Stavidine + lamivudine + nevirapine VERSUS Zudovudine+lamivudine+nevirapine IN HIV patients in South Africa,21124202,HIV patients in South Africa,Stavidine + lamivudine + nevirapine,Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.,Zudovudine+lamivudine+nevirapine,NW
2011-01-07271,2011,Bendavid                         2011 AIDS,Dominated,Zidovudine + lamivudine + efavirenz VERSUS Tenofovir + lamivudine + nevirapine IN HIV patients in South Africa,21124202,HIV patients in South Africa,Zidovudine + lamivudine + efavirenz,Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.,Tenofovir + lamivudine + nevirapine,NW
2010-01-06486,2010,Athan 2010 AIDS,110,Low cost CD4 T-cell counting VERSUS WHO staging only IN HIV-infected individuals in the Republic of South Africa and Cote d'Ivoire considering initiating antiretroviral therapy in resource limited settings,20543661,HIV-infected individuals in the Republic of South Africa and Cote d'Ivoire considering initiating antiretroviral therapy in resource limited settings,Low cost CD4 T-cell counting,Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings.,WHO staging only,NE
2010-01-06486,2010,Athan 2010 AIDS,1200,Annual routine t CD4 T-cell counting VERSUS WHO staging only IN HIV-infected individuals in the Republic of South Africa and Cote d'Ivoire considering initiating antiretroviral therapy in resource limited settings,20543661,HIV-infected individuals in the Republic of South Africa and Cote d'Ivoire considering initiating antiretroviral therapy in resource limited settings,Annual routine t CD4 T-cell counting,Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings.,WHO staging only,NE
2009-01-05500,2009,Sinanovic 2009 Vaccine,1300,Vaccination of 12-year-old girls followed by screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30 VERSUS Screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30 IN Women screened for cervical cancer from societal perspective,19698807,Women screened for cervical cancer from societal perspective,Vaccination of 12-year-old girls followed by screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30,The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.,Screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30,NE
2009-01-05500,2009,Sinanovic 2009 Vaccine,1800,Vaccination of 12-year-old girls followed by screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30 VERSUS Screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30 IN Women screened for cervical cancer from health care perspective,19698807,Women screened for cervical cancer from health care perspective,Vaccination of 12-year-old girls followed by screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30,The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.,Screening using conventional cervical cytology is performed 3 times at 10-year intervals starting at age 30,NE
2009-01-04282,2009,Vijayaraghavan 2009 Gynecol Oncol,1200,HPV DNA testing followed by colposcopy for all HPV-positive women VERSUS Conventional cytology IN Women aged 30 in South Africa,19081611,Women aged 30 in South Africa,HPV DNA testing followed by colposcopy for all HPV-positive women,Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.,Conventional cytology,NE
2009-01-04282,2009,Vijayaraghavan 2009 Gynecol Oncol,1500,Simultaneous HPV DNA testing abd conventional cytology co-screening VERSUS Conventional cytology IN Women aged 30 in South Africa,19081611,Women aged 30 in South Africa,Simultaneous HPV DNA testing abd conventional cytology co-screening,Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.,Conventional cytology,NE
2009-01-04282,2009,Vijayaraghavan 2009 Gynecol Oncol,1600,HPV DNA testing followed by cytology for HPV-positive women VERSUS Conventional cytology IN Women aged 30 in South Africa,19081611,Women aged 30 in South Africa,HPV DNA testing followed by cytology for HPV-positive women,Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.,Conventional cytology,NE
2009-01-04282,2009,Vijayaraghavan 2009 Gynecol Oncol,2500,Conventional cytology followed by HPV for equivocal cytology results VERSUS No screening IN Women aged 30 in South Africa,19081611,Women aged 30 in South Africa,Conventional cytology followed by HPV for equivocal cytology results,Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.,No screening,NE
1 2 3 4 5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
